Author:
Lenzi Renato,Edwards Robert,June Carl,Seiden Michael V,Garcia Michael E,Rosenblum Michael,Freedman Ralph S
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference14 articles.
1. Dedrick RL, Meyers CE, Bungay PM: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports. 1978, 62: 2-11.
2. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ, Zighelboim J: Intraperitoneal recombinant a-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study. Cancer Res. 1985, 45: 4447-4453.
3. Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DT: Intraperitoneal human recombinant interferon alpha-2b in minimum residual ovarian cancer. Eur J Cancer. 1990, 26: 353-358.
4. Pujade-Lauraine E, Guastella JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M: Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996, 14: 343-350.
5. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Koal CD, Kunscher AJ, Baldisseri M, Kirkwood JM, Herberman RB: Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997, 15: 3399-3407.
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献